Protocol: PK Bridging ELISA Detecting Total Drug Using Anti-Infliximab Antibodies
Pharmacokinetic (PK) bridging ELISA protocol detects total drug (free, partially and fully bound): For use with Anti-Infliximab Antibody products HCA214 and HCA216P
This method provides a procedure for carrying out a PK ELISA with Anti-Infliximab Antibodies, catalog numbers HCA214 (capture antibody) and HCA216P (detection antibody), and using infliximab for the standard curve. These two antibodies do not inhibit the binding of infliximab to TNFα, therefore this assay can detect total drug (free, partially bound and fully bound). The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.
Payment methods we support: